Ginsenoside Rg3 in Cancer Therapy: Pharmacokinetics, Molecular Mechanisms, and Synergistic Combinations

Area of Science:

• Pharmacology
• Oncology
• Natural Products

Background:

• Ginsenoside Rg3 (Rg3) is a processed Panax ginseng saponin with multitarget anticancer properties.
• Its therapeutic efficacy is influenced by stereochemistry, concentration, and pharmacokinetics.
• Poor bioavailability and rapid clearance necessitate advanced delivery systems.

Purpose of the Study:

• To systematically review the anticancer potential of Rg3.
• To analyze its pharmacokinetic profile, molecular mechanisms, and clinical applications.
• To evaluate Rg3's synergistic effects and potential in precision cancer therapy.

Main Methods:

• Comprehensive literature searches of PubMed and Web of Science databases.
• Inclusion of peer-reviewed preclinical and clinical studies on Rg3.
• Systematic integration of data on pharmacokinetics, efficacy, and mechanisms.

Main Results:

• Rg3 exhibits broad-spectrum anticancer activity against multiple solid tumors and hematological malignancies.
• Mechanistically, Rg3 modulates proliferation, apoptosis, angiogenesis, and immune evasion via key signaling pathways.
• Rg3 demonstrates synergistic effects with conventional therapies, reverses drug resistance, and reduces toxicity.

Conclusions:

• Rg3 possesses significant anticancer potential, supported by extensive preclinical and clinical evidence.
• Nanocarrier systems improve Rg3's pharmacokinetic profile and tumor accumulation.
• Rg3 offers a promising framework for developing novel combination strategies in precision cancer therapy.